Skip to content
TRAXFirst Tracks Biotherapeutics, Inc.

Earnings

When First Tracks Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

6 quarters. Mar 31, 2025 to Sep 30, 2026. mixed units.

Quarter by quarter

Q3 2026-$31.36MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 3, 2026, after the closeThe release+5.9%by the close of Nov 4
    Revenue
    —
    —
    Net income
    -$31.36M
    N/M
    EPS
    -$0.88
    N/M
  2. Q2 2026Aug 12, 2026, after the closeThe release4.8%by the close of Aug 13
    Revenue
    —
    —
    Net income
    -$33.37M
    N/M
    EPS
    -$0.95
    N/M
  3. Q1 2026May 14, 2026, after the closeThe release7.1%by the close of May 15
    Revenue
    —
    —
    Net income
    -$50.48M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · after-hoursNov 3, 202634 d10-Q——-$0.88+5.9%
Q2 2026Jun 30, 2026Aug 12, 2026 · after-hoursAug 12, 202643 d10-Q——-$0.954.8%
Q1 2026Mar 31, 2026May 14, 2026 · after-hoursMay 14, 202644 d10-Q———7.1%
FY 2025
Q3 2025Sep 30, 2025——————-$1.50—
Q2 2025Jun 30, 2025——————-$1.47—
Q1 2025Mar 31, 2025————————

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026445430
10-QAug 12, 2026346931
10-QMay 14, 2026224190

Provenance

ProvenanceData status and checks

First Tracks Biotherapeutics, Inc. · CIK 2091349 · Engraved from SEC EDGAR